mProX™ Human CDC42BPG Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryBased on this stable cell line, we also provide cell-based in vitro assays to evaluate the effects of your compounds or antibodies.
| Sub Cat | Product Name | Target Protein Species | Host Cell Type | Assay Types | Inquiry | Datasheet |
|---|---|---|---|---|---|---|
| S01YF-1122-KX1103 | Magic™ Human DMPK2(CDC42BPG) in Vitro Assay | Human | Kinase Assay |
Product Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
Charles
Verified Customer
Linda
Verified Customer
Any questions about our products? Please visit our frequently asked questions page.
Published Data
Fig.1 Regulation of CD137L, CDC42BPG and FST by p53.
Two hours after each siRNA was transfected, U2OS cells were exposed to ADR (2 μg/ml) for a duration of 24 hours. A qPCR was carried out 36 hours post-treatment. As a control, siRNA targeting EGFP was employed. β-actin was employed to standardize the expression levels.
Ref: Tsuda, Yusuke, et al. "Identification of a p53 target, CD137L, that mediates growth suppression and immune response of osteosarcoma cells." Scientific Reports 7.1 (2017): 10739.
Pubmed: 28878391
DOI: 10.1038/s41598-017-11208-x
Research Highlights
Hyperuricemia and chronic renal disease are major global health issues. Numerous genetic variations linked to these illnesses have been found by recent genome-wide association studies. But the majority of research has been done using a cross-sectional approach.
Yasukochi, Yoshiki, et al. "Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population." Molecular genetics and genomics 293 (2018): 371-379.
Pubmed:
29124443
DOI:
10.1007/s00438-017-1394-1
It was discovered that three novels direct p53 target genes, CD137L, CDC42 binding protein kinase gamma, and follistatin, have growth-suppressive effects on osteosarcoma cell lines.
Tsuda, Yusuke, et al. "Identification of a p53 target, CD137L, that mediates growth suppression and immune response of osteosarcoma cells." Scientific Reports 7.1 (2017): 10739.
Pubmed:
28878391
DOI:
10.1038/s41598-017-11208-x
